GLP-1 drugs may not help every form of heart failure, researchers warn

GLP-1 receptor agonists have been credited with reducing heart failure hospitalization in pooled analyses, but a new commentary argues that the benefit may not extend evenly across the full spectrum of heart failure phenotypes. Writing in Cardiovascular Diabetology – Endocrinology Reports, author Jianxin Deng highlights a key gap in the evidence base: whether the observed reduction in hospitalizations reflects a true class effect of the drugs, or whether it is confined to specific, metabolically defined subgroups of patients.

The commentary draws a distinction between two very different bodies of evidence. Dedicated trials showing efficacy in obesity-associated heart failure with preserved ejection fraction enrolled highly selected populations, meaning their results may not generalize to broader patient groups. By contrast, the cardiovascular outcome trials included in pooled analyses lacked detailed heart failure phenotyping, making it impossible to determine which phenotypes actually drove the reported hospitalization reductions.

Evidence for GLP-1 receptor agonists in heart failure with reduced ejection fraction remains limited, according to the commentary.

To resolve the uncertainty, the author calls for standardized heart failure phenotyping and phenotype-specific analyses in future research. Such an approach would clarify whether the hospitalization benefit is a class effect of GLP-1 receptor agonists or is preferentially confined to metabolically defined subgroups. Until that work is done, the commentary concludes, the question of which heart failure phenotypes truly benefit from these drugs remains open.

Subject of Research: Whether GLP-1 receptor agonists reduce heart failure hospitalization across different heart failure phenotypes

Article Title: Which heart failure phenotypes benefit from GLP-1 receptor agonists?

Article References: Deng, J. (2026). Which heart failure phenotypes benefit from GLP-1 receptor agonists?. Cardiovascular Diabetology – Endocrinology Reports, 12(1), Article 58. https://doi.org/10.1186/s40842-026-00328-x

Image Credits: AI Generated

DOI: 10.1186/s40842-026-00328-x

Keywords: GLP-1 receptor agonists, heart failure, HFpEF, HFrEF, hospitalization, cardiovascular outcome trials, phenotyping, obesity, Cardiovascular Diabetology, commentary, heart, failure